BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30314992)

  • 1. Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I.
    Barnett S; Ogungbenro K; Ménochet K; Shen H; Humphreys WG; Galetin A
    J Pharmacol Exp Ther; 2019 Jan; 368(1):125-135. PubMed ID: 30314992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
    Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
    Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
    Kunze A; Ediage EN; Dillen L; Monshouwer M; Snoeys J
    Clin Pharmacokinet; 2018 Dec; 57(12):1559-1570. PubMed ID: 29663259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects.
    Shen H; Chen W; Drexler DM; Mandlekar S; Holenarsipur VK; Shields EE; Langish R; Sidik K; Gan J; Humphreys WG; Marathe P; Lai Y
    Drug Metab Dispos; 2017 Aug; 45(8):908-919. PubMed ID: 28576766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.
    Barnett S; Ogungbenro K; Ménochet K; Shen H; Lai Y; Humphreys WG; Galetin A
    Clin Pharmacol Ther; 2018 Sep; 104(3):564-574. PubMed ID: 29243231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative prediction of OATP1B-mediated drug-drug interactions using endogenous biomarker coproporphyrin I.
    Takubo H; Bessho K; Watari R; Shigemi R
    Xenobiotica; 2022 Apr; 52(4):397-404. PubMed ID: 35638858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs.
    Mori D; Kimoto E; Rago B; Kondo Y; King-Ahmad A; Ramanathan R; Wood LS; Johnson JG; Le VH; Vourvahis M; David Rodrigues A; Muto C; Furihata K; Sugiyama Y; Kusuhara H
    Clin Pharmacol Ther; 2020 Apr; 107(4):1004-1013. PubMed ID: 31628668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method.
    Chan GH; Houle R; Zhang J; Katwaru R; Li Y; Chu X
    Drug Metab Dispos; 2023 Sep; 51(9):1089-1104. PubMed ID: 37137718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
    Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
    Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.
    Kimoto E; Costales C; West MA; Bi YA; Vourvahis M; David Rodrigues A; Varma MVS
    Clin Pharmacol Ther; 2022 Feb; 111(2):404-415. PubMed ID: 34605015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
    Gu X; Wang L; Gan J; Fancher RM; Tian Y; Hong Y; Lai Y; Sinz M; Shen H
    Drug Metab Dispos; 2020 Aug; 48(8):724-734. PubMed ID: 32482623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey.
    Ufuk A; Kosa RE; Gao H; Bi YA; Modi S; Gates D; Rodrigues AD; Tremaine LM; Varma MVS; Houston JB; Galetin A
    J Pharmacol Exp Ther; 2018 Jun; 365(3):688-699. PubMed ID: 29643253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
    Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
    Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease.
    Takita H; Scotcher D; Chu X; Yee KL; Ogungbenro K; Galetin A
    Clin Pharmacol Ther; 2022 Sep; 112(3):615-626. PubMed ID: 35652251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.
    Yoshikado T; Toshimoto K; Maeda K; Kusuhara H; Kimoto E; Rodrigues AD; Chiba K; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):739-747. PubMed ID: 30175555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression.
    Zhang Y; Chen C; Chen SJ; Chen XQ; Shuster DJ; Puszczalo PD; Fancher RM; Yang Z; Sinz M; Shen H
    J Pharmacol Exp Ther; 2020 Oct; 375(1):139-151. PubMed ID: 32719071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry.
    Kikuchi R; Chothe PP; Chu X; Huth F; Ishida K; Ishiguro N; Jiang R; Shen H; Stahl SH; Varma MVS; Willemin ME; Morse BL
    Clin Pharmacol Ther; 2023 Dec; 114(6):1170-1183. PubMed ID: 37750401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
    Cheung KWK; Yoshida K; Cheeti S; Chen B; Morley R; Chan IT; Sahasranaman S; Liu L
    Drug Metab Dispos; 2019 Sep; 47(9):966-973. PubMed ID: 31266752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B.
    Feng S; Bo Q; Coleman HA; Charoin JE; Zhu M; Xiao J; Jin Y
    J Clin Pharmacol; 2021 Aug; 61(8):1027-1034. PubMed ID: 33460165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repression of Organic Anion Transporting Polypeptide (OATP) 1B Expression and Increase of Plasma Coproporphyrin Level as Evidence for OATP1B Downregulation in Cynomolgus Monkeys Treated with Chenodeoxycholic Acid.
    Zhang Y; Chen SJ; Chen C; Chen XQ; Chatterjee S; Shuster DJ; Dexter H; Armstrong L; Joshi EM; Yang Z; Shen H
    Drug Metab Dispos; 2022 Aug; 50(8):1077-1086. PubMed ID: 35636769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.